A biotech company pioneering transposases for cell line engineering claims to have widened the applications of these tools. Oren Beske, PhD, gave a talk at BioProcess International, about how ATUM is ...

Modern therapeutics are shifting from their reliance on small molecules to biologics produced by cultured cells. The development and production of those biologics increasingly rely on computationally ...

A new study published in Engineering provides mechanistic insights into live-cell glycocalyx engineering and supports the rational design of next-generation adoptive cell therapies (ACTs) against B ...

MSCs improve therapeutic consistency and precision across cell therapies. The approach also supports scalable allogeneic ...

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important type of human immune cell—known as helper T cells—from stem cells in a ...

New York Blood Center Enterprises’ (NYBCe) Lindsley F. Kimball Research Institute (LFKRI) today announced a scientific collaboration with Biohub to develop optimized methodologies for deriving induced ...

NYBCe and CZ Biohub will derive iPSC lines from cord blood's immune cells, creating shared, broadly compatible resources for cell therapy, disease modelling, and AI-driven drug development.

To accelerate discovery, scientists from ATCC and the Broad Institute collaborated to engineer a panel of drug-resistant NSCLC models using CRISPR gene editing and gene overexpression techniques.

WUHAN, HUBEI PROVINCE, CHINA, February 15, 2026 /EINPresswire.com/ — In the complex landscape of life science research, selecting the right cellular model is a ...